No back-peddling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977)
In Azurity v. Alkem the US Court of Appeals for the Federal Circuit (CAFC) affirmed the District of Delaware's ruling that Alkem's...
top of page
Beware of boilerplate: Practical lessons for patent drafting from G1/24 (Claim interpretation)
Following the high profile hearing last month, we are now all waiting with bated breath for the written decision of the Enlarged Board of...
G 2/21 applied to software inventions (T 0687/22)
The EPO Board of Appeal decision in T 0687/22 confirms beyond doubt the relevance of G 2/21 to software inventions. The decision in ...
Use versus process patents: Implications for novelty and scope (T 1913/21)
The recent decision T 1913/21 highlights a crucial differentiation between second non-medical use claims and process claims. The Board...
Too broad, too early? AI platform for cell analysis found to lack technical character and sufficiency (T 0660/22, Cell analysis/NIKON)
The decision in T 0660/22 combines two hot topics, AI and cells! The patent application at issue related to a method for analysing...
The benefits and pitfalls of drug manufacturing IP (T 2543/22)
The Board of Appeal decision in T 2543/22 relates to a manufacturing method for preparing a therapeutic peptide. The Board of Appeal...
A new mode of administration is a new specific medical use (but not necessarily inventive) (T 0295/22)
The Board of Appeal decision in T 0295/22 tackles the question of whether a new mode of administration of a drug should be considered a...
bottom of page